TY - JOUR
T1 - A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics
AU - Ruggiero, G. M.
AU - Laini, V.
AU - Mauri, M. C.
AU - Ferrari, V. M S
AU - Clemente, A.
AU - Lugo, F.
AU - Mantero, M.
AU - Redaelli, G.
AU - Zappulli, D.
AU - Cavagnini, F.
PY - 2001
Y1 - 2001
N2 - 1. The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria. 2. 13 patients, mean weight 37.61 kg ± 9.80 SD, were treated with clomipramine at a mean dosage of 57.69 mg ± 25.79 SD; 10 patients, mean weight 40.90 kg ± 6.98 SD, were treated with fluoxetine at a mean dosage of 28.00 mg ± 10.32 SD; 12 patients, mean weight 38.41 kg ± 8.33 SD, were treated with amisulpride at a mean dosage of 50.00 mg ± 0.00 SD. 3. Clinical evaluation was carried out under single-blind condition at basal time and after three months by a structured clinical interview, the Eating Disorder Interview based on Long Interval Follow-up Evaluation (LIFE II BEI). 4. Patients treated with amisulpride showed a more significant increase (p=O.O16) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted.
AB - 1. The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria. 2. 13 patients, mean weight 37.61 kg ± 9.80 SD, were treated with clomipramine at a mean dosage of 57.69 mg ± 25.79 SD; 10 patients, mean weight 40.90 kg ± 6.98 SD, were treated with fluoxetine at a mean dosage of 28.00 mg ± 10.32 SD; 12 patients, mean weight 38.41 kg ± 8.33 SD, were treated with amisulpride at a mean dosage of 50.00 mg ± 0.00 SD. 3. Clinical evaluation was carried out under single-blind condition at basal time and after three months by a structured clinical interview, the Eating Disorder Interview based on Long Interval Follow-up Evaluation (LIFE II BEI). 4. Patients treated with amisulpride showed a more significant increase (p=O.O16) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted.
KW - Amisulpride
KW - Clomipramine
KW - Fluoxetine
KW - Psychopharmacotherapy
KW - Re-feeding treatment
KW - Restricting anorexia nervose
UR - http://www.scopus.com/inward/record.url?scp=0034892423&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034892423&partnerID=8YFLogxK
U2 - 10.1016/S0278-5846(01)00174-9
DO - 10.1016/S0278-5846(01)00174-9
M3 - Article
C2 - 11444677
AN - SCOPUS:0034892423
VL - 25
SP - 1049
EP - 1059
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
IS - 5
ER -